DexCom (DXCM)
(Real Time Quote from BATS)
$69.18 USD
-0.52 (-0.75%)
Updated Sep 24, 2024 10:24 AM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Company Summary
San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
According to an article by Mordor Intelligence, the CGM devices market is expected to witness a CAGR of nearly 12.9% between 2021 and 2029, with strong growth in the Asia Pacific region. The market is expected to reach $21.34 billion in 2029.
DexCom’s product portfolio ...
Company Summary
San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
According to an article by Mordor Intelligence, the CGM devices market is expected to witness a CAGR of nearly 12.9% between 2021 and 2029, with strong growth in the Asia Pacific region. The market is expected to reach $21.34 billion in 2029.
DexCom’s product portfolio consists of CGM devices targeting type 1 and type 2 diabetes patients. The company received FDA approval for its first product in 2006 and has continued to add upgraded devices to its portfolio. The company currently focuses on its latest generation systems, the Dexcom G6 (2018 approval) and G7 (2023 approval) integrated CGM (iCGM) devices. Apart from these iCGM products, the company has DexCom One and One+ sensors offering similar capabilities like G6 and G7 except for integration of digitally connected devices, including automated insulin dosing systems. The company markets One (approval 2022) and One+ (approval 2024) sensors only in Europe. While G6 & G7 sensors are approved for use in any type 1 or 2 diabetic patient above two years of age, One & One+ sensors are approved for use in similar patient populations but using insulin. The company received approval for its first OTC glucose sensor, Stelo, in March 2024, for use in type 2 diabetic patients.
However, market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions.
2023 at a Glance
For the full-year 2023, the company reported adjusted EPS of $1.52, up 74.7% from 2022. Full-year 2023 revenues came in at $3.62 billion, up 24% year over year.
DexCom generated nearly 93% of revenues from its sensors and the rest from the sale of transmitters and receivers during the first quarter of 2024. In the first quarter, U.S. sales increased 24.2% to $653.2 million (71% of total revenue) while international sales improved 24.3% to $267.8 million (29% of total revenue).
General Information
DexCom, Inc
6340 SEQUENCE DRIVE
SAN DIEGO, CA 92121
Phone: 858-200-0200
Fax: 858-200-0201
Email: investor-relations@dexcom.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/24/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.44 |
Current Year EPS Consensus Estimate | 1.69 |
Estimated Long-Term EPS Growth Rate | 19.10 |
Exp Earnings Date | 10/24/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 69.70 |
52 Week High | 141.99 |
52 Week Low | 62.34 |
Beta | 1.18 |
20 Day Moving Average | 3,911,831.50 |
Target Price Consensus | 96.18 |
4 Week | -5.39 |
12 Week | -37.86 |
YTD | -43.83 |
4 Week | -7.07 |
12 Week | -40.51 |
YTD | -53.15 |
Shares Outstanding (millions) | 400.73 |
Market Capitalization (millions) | 27,930.66 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 41.24 |
Trailing 12 Months | 39.83 |
PEG Ratio | 2.16 |
vs. Previous Year | 26.47% |
vs. Previous Quarter | 34.38% |
vs. Previous Year | 15.26% |
vs. Previous Quarter | 9.04% |
Price/Book | 11.47 |
Price/Cash Flow | 33.68 |
Price / Sales | 7.10 |
6/30/24 | 31.41 |
3/31/24 | 31.01 |
12/31/23 | 28.31 |
6/30/24 | 10.84 |
3/31/24 | 10.29 |
12/31/23 | 9.74 |
6/30/24 | 2.82 |
3/31/24 | 2.90 |
12/31/23 | 2.84 |
6/30/24 | 2.48 |
3/31/24 | 2.53 |
12/31/23 | 2.48 |
6/30/24 | 18.00 |
3/31/24 | 17.71 |
12/31/23 | 16.94 |
6/30/24 | 16.95 |
3/31/24 | 16.82 |
12/31/23 | 14.95 |
6/30/24 | 20.51 |
3/31/24 | 20.48 |
12/31/23 | 19.61 |
6/30/24 | 6.07 |
3/31/24 | 5.65 |
12/31/23 | 5.35 |
6/30/24 | 2.64 |
3/31/24 | 2.73 |
12/31/23 | 2.89 |
6/30/24 | 1.00 |
3/31/24 | 1.08 |
12/31/23 | 1.18 |
6/30/24 | 50.04 |
3/31/24 | 52.02 |
12/31/23 | 54.06 |